Very insightful discussion on Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life by @JavedButler1 in #THT2022

@LindenfeldJoa @TheHeartBeat3 @LiviuKlein @HFpEF @RyanTedfordMD @GreggWStone @SKumar_UTHealth @gtsayer @SrihariNaiduMD @purviparwani
📌SGLT2i clinical benefits is seen irrespective of baseline health status

#SGLT2i improve health status and quality of life early and sustained in both patients with #HFrEF and #HFpEF
@JavedButler1
@ShelleyZieroth @SeguraCardio @docbhardwaj @docbhardwaj @KevinShahMD #THT2022
#Canagliflozin Improves Quality of Life in HF Patients in #CHIEF-HF

One of the strengths of CHIEF-HF is the diversity of participants, noting that 14% of patients were Black and 45% were female @JavedButler1 #THT2022 @JamalRanaMD @crfheart @SantosGallegoMD @ShelleyZieroth
#SGLT2 inhibition is beneficial in HF patients regardless of EF, except in patients with an LVEF ≥65%.

The benefits of #SGLT2I are that they are mainly from reducing HF hospitalizations rather than mortality. @crfheart #THT2022 @JJheart_doc @JavedButler1 @HFpEF

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Henry Han, MBBS, MD

Henry Han, MBBS, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @HanCardiomd

Nov 4, 2021
Multimodality imaging in patients with HFpEF: an expert consensus document of the European Association of Cardiovascular Imaging #EACVI #MMI #HFpEF academic.oup.com/ehjcimaging/ad… @ESC_Journals @Cosyns @alessia_gimelli @ThorEdvardsen @VDelgadoGarcia @bogdan_popescu1 @JaeKOh2
This expert consensus document from the #EACVI provides recommendations regarding how to determine elevated LV filling pressure in the setting of suspected #HFpEF and how to use multimodality imaging to determine specific aetiologies in patients with HFpEF @EACVIPresident
📌Mechanisms of LV diastolic dysfunction include impaired relaxation, attenuated restoring forces, and increased passive elastic stiffness that leads to elevated LV filling pressure

📌The presence of LV hypertrophy and dilated LA provides support for the #HFpEF diagnosis
Read 5 tweets
Aug 30, 2021
Iron deficiency as a therapeutic target in heart failure - new evidence, new guidelines

New evidence from AFFIRM-AHF ‒ implications for clinical practice with ⬆️QoL
#ESCCongress @ESC_Journals @escardio @ShelleyZieroth @hvanspall @DrNasrien @SilCastelletti @DrMarthaGulati
New evidence from AFFIRM-AHF ‒ implications for clinical practice on cost effectiveness and QoL

#ESCCongress @ESC_Lavinia @escardio @ESCardioNews @ShelleyZieroth @JavedButler1 @rachkataria @AndreasGevaert @AndrewJSauer @pabeda1 @BSHeartFailure @FH_Verbrugge @DrRyanPDaly
Very insightful presentation by @JavedButler1 on New evidence from meta-analyses ‒ lessons to learn on the benefits of intravenous ferric carboxymaltose in HF

#ESCCongress @JavedButler1 @DrNasrien @MihaiTrofenciuc @pabeda1 @AndrewJSauer @NMHheartdoc @hvanspall @MajaCikes
Read 5 tweets
Aug 29, 2021
Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? - Joint with (ISCP)

Prevention of thromboembolism in COVID-19
#ESCCongress @escardio @ESC_Lavinia @Steph_Achenbach @susannaprice @mmamas1973 @fhussain73 @DrJennHaythe md
Read 8 tweets
Aug 29, 2021
Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

📌Finerenone - Novel , selective , non- steroidal MRA

#ESCCongress @lamcardio @BiykemB @MihaiTrofenciuc @pabeda1 @AndrewJSauer @MeralKayikcoglu @ErinMichos @DrMarthaGulati @DavidLBrownMD @JamalRanaMD
Finerenone has a favorable safety profile across a wide dose range in patients with CKD and T2DM receiving a RAS blocker
#ESCCongress

@CMichaelGibson @JamalRanaMD @DrMarthaGulati @AnastasiaSMihai @onco_cardiology @DavidLBrownMD @biljana_parapid @AndrewJSauer @ShelleyZieroth
Read 5 tweets
Aug 28, 2021
FIGARO -DKD

FIGARO-DKD Finds Finerenone Offers CV Benefits in Mild to Moderate Kidney Disease With T2D; Cuts HF Hospitalization 29% @escardio #ESCCongress @JJheart_doc @AnastasiaSMihai @ESC_Journals @ShelleyZieroth @mmamas1973 @hvanspall @JavedButler1 @DrNasrien @aayshacader
A statistically significant 13% lower risk among those treated with finerenone, a benefit that was driven by a reduction in HHF (HR 0.71; 95% CI 0.56-0.90)

@escardio #ESCCongress @ShelleyZieroth @hvanspall @mmamas1973 @AnastasiaSMihai @DrNasrien @lamcardio @JavedButler1
The combined patient-level analysis of FIGARO-DKD and FIDELITY-DKD included 13,171 patients with #T2DM of whom 40% had preserved kidney function as defined by the eGFR ≥ 60 mL/min/1.73 m2 but elevated UACR

@escardio #ESCCongress @ESC_Journals @lamcardio @FaiezZANNAD
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(